Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentaxim
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pentaxim is a pentavalent combination vaccine developed by Sanofi Pasteur for the active immunization of infants and children against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive infections caused by Haemophilus influenzae type b (such as meningitis and septicaemia). The vaccine consists of diphtheria and tetanus toxoids, acellular pertussis components (pertussis toxoid and filamentous haemagglutinin), inactivated poliovirus (types 1, 2, and 3), and a Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. It is designed to reduce the number of injections required for primary vaccination and booster doses in early childhood, thereby improving compliance and coverage.
- Brand names
- Pentaxim
- Other names
- DTaP-IPV/Hib vaccineDTacP-IPV//PRP~TPentavalent vaccine
02
Targets
FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Pentaxim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentaxim.